Autoimmune hepatitis
Autoimmune hepatitis is a chronic inflammatory hepatitis, four times more common in women, marked by elevated aminotransferases, autoantibodies, and hypergammaglobulinemia, confirmed by liver biopsy after excluding other causes. Treatment is immunosuppression with prednisone, usually combined with azathioprine, continued for at least 2 to 3 years before withdrawal is considered.
- Topic reviewThe full article, organized the way the exam asks it.
- ABIM-format MCQsVignettes with an explanation for every wrong answer.
- Key factsThe numbers and thresholds worth memorizing, up front.
- AI tutorMedBrain answers the question you're stuck on.
What this article covers
- Overview
Definition: autoimmune hepatitis (AIH) is a chronic inflammatory hepatitis driven by loss of tolerance to hepatocyte antigens, producing a spectrum from asymptomatic aminotransferase elevation to acute liver failure.
- Epidemiology
Sex distribution: about four times more common in women than men.
- Risk factors
Female sex: the dominant demographic risk factor.
- Pathophysiology
Loss of self-tolerance: autoreactive T cells and autoantibody-producing B cells target hepatocyte antigens, producing this in genetically susceptible individuals.
- Clinical features
Highly variable presentation: ranges from asymptomatic elevation of aminotransferase levels found incidentally, to extrahepatic constitutional symptoms, to acute liver failure; no single presentation excludes the diagnosis.
- Differential diagnosis
Acute viral hepatitis (A, B, C, or E): fever, jaundice, and elevated aminotransferases, but positive viral serologies and exposure history distinguish it and autoantibodies are typically absent…
- Diagnosis
Confirm the diagnosis with biochemistry, serology, exclusion of mimics, and liver histology together; no single test is diagnostic alone.
- Management
First, assess acuity to route the patient.
- Complications
Acute liver failure: the most urgent complication, presenting with encephalopathy and coagulopathy and requiring emergent transplant-center transfer.
- Prognosis
Outlook is treatment-dependent: most patients who receive and adhere to immunosuppression achieve biochemical remission and avoid progression to cirrhosis or liver failure.
- Prevention
No primary prevention exists because the trigger for loss of self-tolerance is not a modifiable exposure; prevention instead targets relapse and treatment toxicity.
Read the whole article
Subscribing to Internal Medicine opens every article, the full question bank and MedBrain, on the web, iPhone and Android.
Related articles
- Acute liver failure
Acute liver failure is the abrupt onset of hepatic synthetic dysfunction, defined by coagulopathy with an INR of 1.5 or higher plus any grade of hepatic encephalopathy, occurring within 26 weeks of illness onset in a patient without preexisting liver disease. Acetaminophen overdose is the leading cause in the United States, and management centers on N-acetylcysteine when acetaminophen is implicated, intensive supportive care, and early referral to a liver transplant center.
- Cirrhosis
Cirrhosis is end-stage hepatic fibrosis with regenerative nodules, staged as compensated or decompensated by the onset of ascites, variceal hemorrhage, encephalopathy, or jaundice. Severity is graded by Child-Pugh class and MELD, and management centers on treating the underlying cause, surveillance for varices and hepatocellular carcinoma, and timely transplant referral once decompensation appears.
- Primary biliary cholangitis
Primary biliary cholangitis is an autoimmune, T cell-mediated destruction of small and medium intrahepatic bile ducts that presents with fatigue and pruritus in middle-aged women and a cholestatic liver chemistry pattern. Diagnosis requires two of three criteria (elevated alkaline phosphatase, positive antimitochondrial antibody, compatible biopsy), and lifelong ursodeoxycholic acid is first-line treatment, with obeticholic acid or fibrates added for inadequate biochemical response.
- Primary sclerosing cholangitis
Primary sclerosing cholangitis is an autoimmune fibroinflammatory disease of the large bile ducts, occurring mostly in young men and associated with inflammatory bowel disease, chiefly ulcerative colitis, in 80 to 90% of cases. MRCP showing multifocal strictures and dilations confirms the diagnosis, no drug alters progression, and management centers on endoscopic dilation of dominant strictures, surveillance for cholangiocarcinoma and colorectal cancer, and liver transplantation for advanced disease.
- Wilson disease
Wilson disease is an autosomal recessive disorder of the ATP7B copper-transporting ATPase causing toxic copper accumulation in the liver, brain, and cornea, presenting with hepatic and/or neuropsychiatric disease usually before age 40; diagnosis rests on ceruloplasmin, urinary copper, and Kayser-Fleischer rings, and lifelong treatment is chelation with penicillamine or trientine, or zinc, unless liver transplant is required.
- Hemochromatosis
Hemochromatosis is a disorder of iron overload, most often hereditary HFE C282Y homozygosity causing hepcidin deficiency and excess intestinal iron absorption, that deposits iron in the liver, pancreas, heart, joints, skin, and pituitary. Screening rests on fasting transferrin saturation and ferritin, confirmation on HFE genetic testing, and treatment on regular therapeutic phlebotomy to a target ferritin of 50 to 100 ng/mL.
- Hepatitis B virus (HBV) infection
Hepatitis B virus is a bloodborne and sexually transmitted DNA virus that causes acute hepatitis and, when infection becomes chronic, progresses through immune-tolerant, immune-active, immune-control, and reactivation phases toward cirrhosis and hepatocellular carcinoma. Diagnosis rests on hepatitis B serology, chronic infection is treated with entecavir or tenofovir, and reactivation during immunosuppression is prevented with prophylactic antiviral therapy.
- Hepatitis C virus (HCV) infection
Hepatitis C virus is a bloodborne RNA virus, transmitted mainly by injection drug use, that produces mostly asymptomatic acute infection and chronic infection in 60% to 80% of cases. Diagnosis is by HCV antibody followed by HCV RNA, and direct-acting antiviral regimens cure more than 90% of patients, reducing but not eliminating the risk of cirrhosis and hepatocellular carcinoma.